INTRODUCTION AND AIM
Diffuse intrinsic pontine glioma (DIPG) and thalamic glioma are diffusely infiltrating midline gliomas, often harboring histone H3K27M mutations, that are most frequently observed in childhood 159 . These tumors have a very high mortality and morbidity as effective treatment strategies still do not exist 11, 160 , despite significant progress in understanding the biological processes that play a role in the development and progression of these tumors 12, 32, 45, 161, 162 . Tumor cells are highly resistant to chemo-and radiotherapy and the presence of the blood brain barrier (BBB) prevents drugs from reaching the bulk tumor and infiltrating tumor cells in sufficient concentrations 15, 163 .
None of the clinical trials that have been performed in DIPG and pHGG, using a large number of different chemotherapeutic agents, including cytostatic agents, targeted antibodies, and small molecule inhibitors, has yet shown a clear benefit that can be translated to standard clinical practice. 162, 164 . Recently, preclinical research has identified pHGG and DIPG cell lines to be sensitive to a number of "classical" cytostatic agents, especially some anthracycline drugs 48 . Anthracyclines are the cornerstones of many chemotherapeutic treatment regimens in a wide variety of cancer types in both adults and children 165 . They are, despite their assumed value, associated with serious adverse events, including debilitating or even life threatening cardiotoxicity 166 . Almost all anthracyclines have been identified as strong substrates of ATP-binding cassette transporters (ABC transporters) P-gP, MRP1 and BCRP causing limited brain penetration 167, 168 . The limited brain penetrance of anthracyclines in brain tumors with an intact BBB, such as diffuse gliomas, might also explain the lack of efficacy when used in the treatment of pHGG including DIPG.
Convection-enhanced delivery (CED) is a local delivery technique that is being
considered a potential drug delivery strategy in DIPG and other brain tumors as it circumferences the BBB 20,69-73 . Drug distribution is facilitated by a pressure gradient at the tip of the infusion catheter, resulting in a bulk flow through the interstitial spaces of the brain 67, 68 . However, choosing the right drug to administer via CED, is difficult: it should be effective against pHGG cells, have favorable chemical properties to enable adequate distribution, and give no-, or limited toxicity in healthy brain tissue 67, 68, 74 . Using liposomal formulations of a drug can potentially improve distribution, bioavailability, biological half-life and efficacy after CED as suggested by several preclinical studies 75, 76, 169, 170 .
| Chapter 4
In this study we aimed to investigate the translational potential of using anthracyclines in the treatment of DIPG and pHGG using CED. Preclinical animal studies have already shown the potential for local delivery of anthracyclines to treat brain tumor models, but no study has investigated the administration of anthracyclines directly to the pons or thalamus. 169, 170 We studied the efficacy of different anthracyclines in vitro, and determined the feasibility of delivering anthracyclines to delicate brain areas such as the brainstem and thalamus.
Subsequently we investigated the efficacy of nanoliposomal and free anthracyclines in treating orthotopic high grade tumors in the brainstem and thalamus in vivo.
MATERIALS & METHODS

TOPIIA expression in DIPG and pHGG
Because TOPIIA expression is associated with good clinical response to treatment with anthracyclines in a number of cancer types 171, 172 , TOPIIA mRNA expression in diffuse intrinsic pontine glioma (DIPG) ( n=27 101 ) and pediatric high grade glioma (pHGG) (n=53 92   ) was determined in silico, using publicly available datasets, and compared to a dataset of ). These datasets include tumor material from biopsy (adult and pHGG and DIPG), resection (adult and pHGG) and autopsy (DIPG). All expression analyses were performed using R2, a web-based microarray analysis and visualization platform (http://r2.amc.nl).
Processing of Tumor Material and Cell Culture
Single cell cultures were established from biopsy samples derived from pediatric glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma and diffuse intrinsic pontine glioma. Informed consent was obtained according to institutionally-approved protocols. Tumor pieces were collected into DMEM (Dulbecco's Modified Eagles Medium, PAA Laboratories GmbH, Pasching, Austria) and washed twice with PBS to remove blood clots. Samples were sliced into small (3-5 mm 3 ) pieces and either mechanically dissociated by filtering through a cell strainer (BD Falcon Biosciences, Bedford, USA), or dissociated by incubation with Accutase (PAA Laboratories GmbH, Pasching, Austria). Single cells were seeded in DMEM-F12, constituted with stable glutamine, 10% fetal bovine serum (PerBio Science Nederland B.V., Etten-Leur, The Netherlands), 1% penicillin/streptomycin (PAA Laboratories GmbH, Pasching, Austria), and 0,5% sodium pyruvate. For primary astrocytes 15% fetal bovine serum was used.
Cells were grown at 37°C in a 5% CO 2 humidified atmosphere. Primary cell cultures 04 75 | Preclinical CED with doxorubicin to treat DIPG genetically characterized using karyotyping or array-CGH as previously described by Veringa et al. 48 The primary HSJD-DIPG-007 cell line was established from DIPG tumor material obtained at Hospital Sant Joan de Déu (Barcelona, Spain) after autopsy from a 6-year-old patient and was confirmed to have a H3F3A (K27M) and ACVR1 (R206H) mutation
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. HSJD-DIPG-007-Fluc was cultured in serum free tumor stem medium (TSM)
as previously described
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.
Drug Treatment
The primary pediatric glioma-and astrocyte cultures were exposed to different anthracycline drugs (idarubicin, epirubicin, mitoxantrone, doxorubicin and daunorubicin) at concentrations ranging from 0.01-1000nM. Fifteen hundred cells were seeded per well in 96-well tissue culture plates. After 96 hours, cell survival was assessed using the Acumen eX3 laser cytometer (TTO Labtech, UK), using 300 mM of 49,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich) as readout. Results were analyzed using Acumen Explorer software, calculating the survival percentage for each compound tested in the assay. Each experiment was performed at least four times.
Drugs
Clinical formulations of idarubicin, epirubicin and daunorubicin used for the in vitro drug screens were supplied by the department of pharmacology of the VU University Medical Center. Free-and pegylated liposomal doxorubicin (PLD) was supplied by 2-BBB Medicines BV (Leiden, The Netherlands). PLD was prepared according to the commercial Doxil/Caelyx preparation method, i.e. using active doxorubicin loading against an ammonium sulfate gradient, as previously described
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. Mean liposome size was 95 nm and contained 2 mg/ml doxorubicin; more than 90% of which was encapsulated in the liposomes. Liposomes were stored in liposome buffer (9.4% sucrose with histidine, 1.55 mg/ml; Sigma-Aldrich, Zwijndrecht, the Netherlands) at 4°C for no longer than three months after production. 
Convection-enhanced delivery in vivo
The CED procedure was performed as previously described by us using a stepped catheter specifically designed for this purpose (figure 2a)
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. In vivo targeting of the brainstem was determined by infusion of trypan blue via CED (figure 2c) and an MRI was performed after infusion of 15 µL of gadolinium 5 uM (Dotarem, Guerbed figure 2d), MRI was performed on mice anesthetized with isoflurane inhalation anaesthesia (1.5 L 0 2 /minute and 2.5% isoflurane) using a preclinical PET-MRI system (Nanoscan system, MEDISO, Budapest, Hungary). T1 weighed images were acquired and analyzed using MIPAV software (Medical Image Processing, Analysis, and Visualization, version 7.2.0). To perform in vivo CED animals were injected with buprenorphine 0.05-1 mg/kg and anesthetized with isoflurane 2-3% in 100% oxygen. After placing the animals in a stereotactic frame on a heated platform (37°C) the CED catheter was introduced into the pons (figure 2b). The coordinates used for CED were the same as used for intracranial injections. During 30 minutes, a total of 15 µL of free doxorubicin, PLD, or vehicle was infused in the brain with a flow velocity of 0.5 µL /min.
After the procedure, animals were returned to their cages to recover and resumed normal active behavior within 3-12 hours. 04 77 | Preclinical CED with doxorubicin to treat DIPG Toxicity study CED toxicity (n=3) with 0.02 mg/ml (35 µM, pons) or 0.2 mg/ml (345µM, pons and thalamus) or 2 mg/ml (3448 µM, pons) doxorubicin or PLD was determined by clinical observations, including weight loss and clinical score. Clinical scores ranged from 0 to 4 and referred to 0: normal active behavior, 1: subtle inactivity or subtle neurological symptoms, 2: mild to moderate inactivity or neurological symptoms, 3: severe neurological symptoms, inactivity, loss of reflexes, inadequate grooming, 4: dead. Half point scores were assigned to mice that were behaving in between two scores. Endpoints due to toxicity were defined as weight loss more than 15%, severe neurological symptoms or severe inactivity. When no clinical endpoints were met, mice were sacrificed six weeks after CED to determine histological toxicity. MTD was selected on clinical features after treatment of three mice (no endpoint reached in all three animals, no clinical score > 2). 
CED and IV efficacy studies
Tissue staining and histological scoring
Haematoxylin and eosin (H&E) staining was performed on 4 μm formalin-fixed, paraffinembedded tissue sections cut in the coronal plane, using a standard H&E protocol. To determine histological toxicity in non-tumor bearing animals, sections were selected at the site of the needle tract and 100 μm both rostrally and posteriorly. Two researchers (AS, TL) and an independent neuropathologist (PW) performed assessment of tissue damage and inflammation. They were blinded to the experimental procedure that the animals underwent. "Clinical" toxicity of doxorubicin is determined by anatomical location CED with a high dose (2 mg/ml) doxorubicin and PLD gave severe clinical toxicity when delivered to the pons (figure 3a). Severe symptoms occurred later after the CED procedure in the PLD treated animals (six days), compared to animals treated with free-doxorubicin (1-3 days) and difference in survival and weight loss was statistically significant (p<0.05, table 1, supplemental figure 1a,b). Eventually, all animals treated in the brainstem with high dose doxorubicin had to be sacrificed due to unacceptable toxicity (figure 3a). Symptoms consisted of weight loss (> 15%) and neurological deficits including paresis and loss of balance. Severe clinical toxicity still occurred with CED to the pons at medium dose (0.2 mg/ ml). All animals in the free-doxorubicin group had to be sacrificed. In the PLD group, one animal had to be sacrificed due to severe symptoms and one animal had clear neurological symptoms but remained active, with weight loss within acceptable limits (<15%), these neurological symptoms regressed after approximately three weeks (table 1, figure 2b). Toxicity of doxorubicin delivered via CED to the thalamus was signifi cantly less pronounced. Medium dose (0.2 mg/ml) of free doxorubicin and PLD could be delivered to the thalamus without any clinical symptoms or weight loss (fi gure 2d). Due to the severe toxicity seen after treatment with 2 mg/ml doxorubicin to the pons, this dose level was not further assessed in the thalamus because of ethical considerations.
RESULTS
Anthracyclines are promising drugs to treat pHGG and DIPG
Histological toxicity of CED is related to dose and formulation of doxorubicin After the mice were sacrifi ced, the brains were histologically analyzed. Animals were sacrifi ced six weeks after treatment unless the mice had to be sacrifi ced at an earlier time After treatment with high dose PLD (2 mg/ml), in the pons tissues obtained six days after treatment consistently revealed a sharply demarcated lesion with incomplete necrosis, dispersed macrophages, and relative sparing of the microvessels (figure 4a). In animals treated with high dose free doxorubicin (2 mg/ml, 1-3 days after treatment) lesions were much less circumscribed and showed insipient necrosis of intervascular tissue and more widespread spongic changes of the neuropil (figure 4b). vaIn brains treated with medium dose doxorubicin to the brainstem (0,2 mg/ml), the tissue damage was more variable. In sharp contrast to the functional neurological defi cits shown in these animals, treatment with 0.2 mg/ml free doxorubicin, histological abnormalities at 2-3 days after treatment were generally absent (fi gure 4c). After treatment with 0.2 mg/ml PLD (brains analyzed 3-6 weeks after CED) some focal gliosis and deposition of iron pigment was found. 04 83 | Preclinical CED with doxorubicin to treat DIPG Six weeks after treatment with low dose free doxorubicin (0.02 mg/ml), the brainstem showed only focal areas with more coarse texture, consistent with astrogliosis (fi gure 4d), similar to what was found in some of the animals that were treated with low dose PLD or CED with vehicle only.
After six weeks of follow-up, brains treated with 0.2 mg/ml free doxorubicin to the thalamus showed clear toxicity characterized by a variably circumscribed area of tissue decay, pericellular thickening of the walls of microvessels, some iron pigment deposition (partly in macrophages) and some proliferation of (myo)fi broblasts (4e&f). Brains treated with PLD 0.2 mg/ml still showed similar but less pronounced lesions (fi gure 4h&g). No histological abnormalities were detected in animals treated with vehicle to the thalamus (fi gure 4i&j). 50 . In order to study CED in diff use high grade gliomas in the thalamus, we established thalamic tumors, using E98FM cells. To this end, we injected E98FM cells into previously validated thalamic coordinates and followed tumor growth in vivo using BLI. A subset of mice injected with E98FM to the thalamus and pons were sacrifi ced at set time points, these brains were analyzed to study size and histology of the tumors (fi gure 5 a-c, g-i).
Others were followed until endpoint (fi gure 5 m-n). Histological assessment showed Survival did not diff er signifi cantly for the whole group however, two out of eight animals treated with PLD had a prolonged decrease in BLI signal and prolonged survival (fi gure 
Tumor size infl uences effi cacy in E98FM tumors treated with PLD via CED
In the effi cacy study, using E98FM-thalamus orthotopic tumors, we found a signifi cant diff erence in bioluminescence signal in the fi rst week after treatment with 0.2 mg/ml PLD, and noticed a survival benefi t in a small proportion (2/8) of mice. To determine whether this survival benefi t was due to a true treatment dependent decrease in tumor burden, or just a random occurrence we studied these animals in more detail.
One noticeable diff erence in animals that responded to treatment was a relatively low bioluminescence signal at start of treatment. Even though median BLI signal was not signifi cantly diff erent between groups, there was a large variation in signal at start of treatment (fi gure 7 a,c, g). We studied response of each individual animal in relation to bioluminescence signal at start of treatment. Thereto we stratifi ed mice into low-(< 10 By doing so, we identified that mice with E98FM-thalamus tumors with low tumor burden showed response (figure 7f) to treatment with PLD 0.2 mg/ml, while no responsive subgroup could be identified in the E98FM-DIPG or HSJD-DIPG-007-Fluc tumors treated either with via CED (PLD or Dox, figure 7c, supplemental 3) or IV ( figure   7i ). In these mice, BLI signal rose exponentially without change, similar to vehicle treated animals. This suggests that tumor size at the start of treatment has substantial influence 
DISCUSSION
Using in silico and in vitro experiments, we identified anthracyclines to be an interesting class of chemotherapeutics that could potentially be used for the treatment of DIPG and pHGG. TOPIIa, which was previously shown to be correlated with anthracycline efficacy in patients 171, 172 , was highly expressed in both DIPG and pHGG compared to normal (HSJD-DIPG-007-Fluc) was used, that was not part of our initial screen. This cell line was intermediately sensitive to doxorubicin in vitro, but no efficacy of low dose doxorubicin via CED could be established using our methods.
Despite the potential, the limited brain penetration of these compounds after systemic 04 89 | Preclinical CED with doxorubicin to treat DIPG delivery greatly limits their clinical use in the treatment of brain tumors. In this study we investigated the feasibility of using CED for local delivery of doxorubicin in the brainstem and thalamus. To our surprise, doxorubicin showed a MTD that was 100 times lower compared to what was previously described to be safe for local delivery in the rat striatum 170 . In our hands, anatomical location clearly influenced clinical toxicity after CED. Tolerable dose when treating mice with CED of doxorubicin in the thalamus was ten times higher compared to the MTD in the brainstem. Meanwhile, histological analysis of brains after CED, showed similar tissue damage in the infused regions. Why this difference in toxicity occurs is not completely understood. We hypothesize that damage to the brainstem, including the pons is more likely to give functional deficits as compared to damage to structures in the thalamus, a phenomenon that is well known in human neurology. Of note, we only studied indirect distribution of doxorubicin by observing spread of histological toxicity. In theory it is possible that distribution of free doxorubicin or PLD differs between pons and thalamus, causing differences in clinical presentation after CED. In this study, we also did not investigate more subtle defects in performance in mice treated with moderately high dose doxorubicin in the thalamus. By doing so, we might have observed functional deficits that now escaped our attention using basic observations. The expected tolerable dose in the thalamus still differed 10 fold from safe concentrations delivered to the striatum of rats described in literature. Although toxicity after CED appears to be related to concentration and not total dose 187 , this could still be explained by the use of a relatively large volume (15 µl) compared to CED studies in most studies using rats (average 20 µl). Furthermore, additional toxicity could be species or even strain related. to treatment in vitro. When using the ten fold higher dose (MTD thalamus), PLD was effective in a slowing down tumor growth in the thalamus. These findings suggest data from supratentorial CED studies cannot be translated directly to design trials to treat infratentorial tumors, and stresses the need for selective agents to avoid excessive toxicity to healthy surrounding tissue, especially to treat tumors in delicate areas of the brain. One preclinical study has already shown that infusing more targeted small molecule inhibitors dasatinib, everolimus and perifosine can be performed safely in the rat pons using long-term CED 189 .
Using our methods, we were able to infuse a substantial area of the pons, but even when treating this area, CED was only effective when tumors were still very small. This is particularly problematic considering the small size of the murine compared to the human pons. Translating this knowledge to a clinical setting would imply only treating small, very early stage tumors. Since this is not the clinical reality of DIPG and thalamic HGG, CED will require drugs with a very high therapeutic index or long-term continuous infusions with lower concentration drugs. To achieve the latter, it will be necessary to apply more sophisticated techniques such as using multiple infusion catheters and computer modeling for targeted infusion 72, 190 or brain-penetrating nanoparticles with regulated release 75, 189 . These projects are currently ongoing, and results from clinical studies are eagerly awaited. To progress CED to an effective treatment strategy for pHGG including DIPG, will be a clinical, biological and technical challenge, requiring a comprehensive multidisciplinary approach. Supplemental figure 3 
